Organization
Duke Cancer Institute Center for Prostate and Urologic Cancers
4 abstracts
Abstract
A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance).Org: Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Duke University Medical Center, Duke University Department of Biostatistics and Bioinformatics,
Abstract
Association between rare pathogenic variants in established cancer risk genes and the diagnosis of single and multiple common cancers: A UK Biobank study.Org: Duke Cancer Institute Center for Prostate and Urologic Cancers and Department of Medicine, Duke University School of Medicine, Durham, NC, NorthShore University HealthSystem Research Institute, Evanston, IL,
Abstract
Real-world intensification beyond androgen deprivation therapy (ADT) in metastatic hormone sensitive prostate cancer (mHSPC) in the United States 2017-2023: An administrative claims database study.Org: Bayer HealthCare Pharmaceuticals Inc., Bayer AG, Bayer Ltd, Bayer Consumer Care AG, Duke Cancer Institute Center for Prostate and Urologic Cancers,
Abstract
A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.Org: Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Virginia Oncology Associates, U.S. Oncology Research, Barbara Ann Karmanos Cancer Institute,